Evidence map›Paper›PMID 39432189›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Evaluating a digital tool for supporting people affected by breast cancer: a prospective randomized controlled trial-the ADAPT study.

Noelle J M C Vrancken Peeters, Olga Husson, Rafal Kulakowski, Emma Hainsworth, Emma Lidington, Sophie E McGrath, Jillian Noble, Leyla Azarang, Susanne Cruickshank, Sofia Georgopoulou

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03866655 (Evaluating a Digital Tool for Supporting Breast Cancer Patients), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03866655 naunknown statusnot on this map

Evaluating a Digital Tool for Supporting Breast Cancer Patients: A Prospective Randomised Controlled Trial

TypeinterventionalSponsorRoyal Marsden NHS Foundation TrustRan2019 to 2022Enrolled165ConditionsBreast CancerArmsOWise
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Effect of a digital tool on breast cancer specific health-related quality of life and psychological distress: secondary results from the ADAPT study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  3. Trial
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Noelle J M C Vrancken PeetersNetherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX, Amsterdam, The Netherlands.
Olga HussonNetherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX, Amsterdam, The Netherlands. o.husson@nki.nl.
Rafal KulakowskiImperial College Health Partners, London, UK.
Emma HainsworthThe Royal Marsden Hospital, London, UK.
Emma LidingtonThe Royal Marsden Hospital, London, UK.
Sophie E McGrathThe Royal Marsden Hospital, London, UK.
Jillian NobleThe Royal Marsden Hospital, London, UK.
Leyla AzarangNetherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX, Amsterdam, The Netherlands.
Susanne CruickshankThe Royal Marsden Hospital, London, UK.
Sofia GeorgopoulouThe Royal Marsden Hospital, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study reports the findings from the ADAPT randomized controlled trial (RCT), concerning the impact of a digital tool for supported self-management in people affected by breast cancer on patient activation as the primary outcome, with health-related quality of life (HRQoL), and health status as secondary outcomes.

methodsWomen with early-stage breast cancer were randomly assigned to standard care (control) or standard care in addition to the breast cancer digital tool (intervention). Data were collected using a demographic questionnaire, the Patient Activation Measure (PAM-13), the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30), and the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) at baseline, 6 weeks, 3 months, 6 months, and 1 year from diagnosis. Linear mixed effect model regression was used to assess the effect of the digital tool over the first year from diagnosis while correcting for intra-participant correlation.

resultsA total of 166 participants were included, with 85 being randomized into the intervention. No significant differences (p > 0.05) in the PAM-13 scores, EORTC QLQ-C30 scales (global QoL, physical functioning, emotional functioning, pain, fatigue), and EQ-5D-5L Index between the control and intervention groups were observed. It is important to note that there was significant non-adherence within the intervention group.

conclusionThe breast cancer digital tool had no statistically significant impact on patient activation, HRQoL, and health status over time compared to standard care alone in women with early-stage breast cancer. Future research should focus on identifying and addressing barriers to digital tool engagement to improve efficacy. Clinical trial information The study was registered at https://clinicaltrials.gov (NCT03866655) on 7 March 2019 ( https://clinicaltrials.gov/study/NCT03866655 ).

Indexed as

Breast NeoplasmsQuality of LifeAdultAgedFemaleHealth StatusHumansMiddle AgedPatient ParticipationProspective StudiesSelf-ManagementSurveys and QuestionnairesBreast cancerEHealthHealth-related quality of life (HRQoL)Health statusPatient activationSupportive care

Identifiers

PMID39432189
PMCPMC11493798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.